ArticleOncology2025

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

Yasutoshi Fujii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.